Literature DB >> 28816644

CYP2B6 Haplotype Predicts Efavirenz Plasma Concentration in Black South African HIV-1-Infected Children: A Longitudinal Pediatric Pharmacogenomic Study.

Riaan Reay1, Collet Dandara2, Michelle Viljoen1, Malie Rheeders1.   

Abstract

South Africa has the highest burden of the human immunodeficiency virus (HIV) infection globally. Efavirenz (EFV), a frequently used drug against HIV infection, displays a relationship between drug concentration and pharmacodynamics effects clinically. However, haplotype-based genetic variation in drug metabolism in a pediatric sample has been little considered in a longitudinal long-term context. CYP2B6 plays a key role in variation of EFV plasma concentration through altered drug metabolism. We report here on a prospective clinical pharmacogenomics/pharmacokinetic study of Bantu-speaking children, importantly, over a period of 24 months post-initiation of EFV-based treatment in South Africa. We characterized the HIV-1-infected children (n = 60) for the CYP2B6 c.516G>T, c.785A>G, c.983T>C, and c.1459C>T single nucleotide polymorphisms (SNPs). These SNPs were determined using polymerase chain reaction/restricted fragment length polymorphism and SNaPshot genotyping. Longitudinal mid-dose EFV plasma concentrations were determined by LC-MS/MS and association analyses with genotypes and haplotypes at 1, 3, and 24 months were performed. The CYP2B6 c.516T/T genotype showed significantly higher EFV plasma concentrations (p < 0.001) compared to non 516T-allele carriers at all three time points. The minor allele frequencies (MAF) for CYP2B6 c.516T, c.785G, c.983C, and c.1459T were 0.410, 0.408, 0.110, and 0.000 respectively. Haplotypes were constructed using CYP2B6 c.516G>T,-c.785A>G and c.983T>C. The haplotype T-G-T presented with significantly increased EFV plasma concentrations compared to the reference G-A-T haplotype at 1, 3, and 24 months (p = 0.009; p = 0.003; p = 0.001), suggesting that the T-G-T haplotype predisposes a risk of EFV plasma concentrations >4 μg/mL. The clinical implications of these pharmacogenomics observations for EFV toxicity and treatment resistance warrant further future research.

Entities:  

Keywords:  CYP2B6; efavirenz; haplotypes; pediatrics; pharmacogenomics

Mesh:

Substances:

Year:  2017        PMID: 28816644     DOI: 10.1089/omi.2017.0078

Source DB:  PubMed          Journal:  OMICS        ISSN: 1536-2310


  8 in total

1.  Distribution of alleles, genotypes and haplotypes of the CYP2B6 (rs3745274; rs2279343) and CYP3A4 (rs2740574) genes in the Malian population: Implication for pharmacogenetics.

Authors:  Yaya Kassogue; Brehima Diakite; Oumar Kassogue; Issa Konate; Kadidiatou Tamboura; Zoumana Diarra; Mamoudou Maiga; Hind Dehbi; Sellama Nadifi; Cheick Bougadari Traore; Bakarou Kamate; Sounkalo Dao; Seydou Doumbia; Guimogo Dolo
Journal:  Medicine (Baltimore)       Date:  2021-07-23       Impact factor: 1.817

2.  Influence of CYP2B6 and CYP3A4 polymorphisms on the virologic and immunologic responses of patients treated with efavirenz-containing regimen.

Authors:  Yaya Kassogue; Brehima Diakite; Mamoudou Maiga; Oumar Kassogue; Issa Konate; Kadidiatou Tamboura; Fousseyni Diarra; Zoumana Diarra; Mahamadou Karamoko Sawadogo; Yaya Goita; Sidi Boula Sissoko; Adama Seydou Sissoko; Nouhoum Guirou; Hind Dehbi; Sellama Nadifi; Sekou Bah; Cheick Bougadari Traore; Bakarou Kamate; Sounkalo Dao; Guimogo Dolo
Journal:  Pharmacogenet Genomics       Date:  2022-06-22       Impact factor: 2.000

3.  The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes: Lessons from Botswana.

Authors:  Monkgomotsi J Maseng; Leabaneng Tawe; Prisca K Thami; Sikhulile Moyo; Ishmael Kasvosve; Vladimir Novitsky; Max Essex; Gianluca Russo; Simani Gaseitsiwe; Giacomo M Paganotti
Journal:  Medicine (Baltimore)       Date:  2022-04-29       Impact factor: 1.817

Review 4.  Pharmacogenetics of Breast Cancer Treatments: A Sub-Saharan Africa Perspective.

Authors:  Keneuoe Cecilia Nthontho; Andrew Khulekani Ndlovu; Kirthana Sharma; Ishmael Kasvosve; Daniel Louis Hertz; Giacomo Maria Paganotti
Journal:  Pharmgenomics Pers Med       Date:  2022-06-21

Review 5.  The Pharmacogenetics of Efavirenz Metabolism in Children: The Potential Genetic and Medical Contributions to Child Development in the Context of Long-Term ARV Treatment.

Authors:  Mei Tan; Megan Bowers; Phil Thuma; Elena L Grigorenko
Journal:  New Dir Child Adolesc Dev       Date:  2020-07-12

6.  Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana.

Authors:  Monkgomotsi J Maseng; Leabaneng Tawe; Prisca K Thami; Kaelo K Seatla; Sikhulile Moyo; Axel Martinelli; Ishmael Kasvosve; Vladimir Novitsky; Max Essex; Gianluca Russo; Simani Gaseitsiwe; Giacomo M Paganotti
Journal:  Pharmgenomics Pers Med       Date:  2021-03-16

Review 7.  Potential challenges to sustained viral load suppression in the HIV treatment programme in South Africa: a narrative overview.

Authors:  Pascal O Bessong; Nontokozo D Matume; Denis M Tebit
Journal:  AIDS Res Ther       Date:  2021-01-06       Impact factor: 2.250

8.  Human cytochrome P450 2B6 genetic variability in Botswana: a case of haplotype diversity and convergent phenotypes.

Authors:  Leabaneng Tawe; Thato Motshoge; Pleasure Ramatlho; Naledi Mutukwa; Charles Waithaka Muthoga; Ghyslaine Bruna Djeunang Dongho; Axel Martinelli; Elias Peloewetse; Gianluca Russo; Isaac Kweku Quaye; Giacomo Maria Paganotti
Journal:  Sci Rep       Date:  2018-03-20       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.